Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7938905 | 0.76 | KDM1A (0.41) | SIGMAR1KDM1AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8067082 | 0.75 | KDM1A (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL8071766 | 0.75 | KDM1A (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL29833737 | 0.74 | ANPEP (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL562559 | 0.74 | ANPEP (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4168243 | 0.74 | ANPEP (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3867845 | 0.74 | ANPEP (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5271544 | 0.74 | ANPEP (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL783223 | 0.74 | ANPEP (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL8049751 | 0.74 | ANPEP (0.42) | KDM1AOPRM1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | SIGMAR1 4626/4885KDM1A 3954/4885OPRM1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.